Startup profile · funding coverage
Aktis Oncology
Clinical-stage radiopharmaceutical company targeting solid tumors with alpha emitters.
Stage
public
Status
public
Coverage
full
Why Aktis Oncology is interesting
Aktis builds miniprotein radioconjugates for cancers underserved by existing radiopharma — incubated at MPM and IPO'd on Nasdaq (AKTS) in Jan 2026.
Key facts
- IPO (Jan 2026): upsized offering on Nasdaq (AKTS); ~$318M gross proceeds (Aktis investor relations)
- Series B (Sep 2024): $175M led by RA Capital; RTW, Janus Henderson participated (PR Newswire)
- Co-investors: no additional institutional investors disclosed in public sources reviewed 2026-07-24
- Source: https://investors.aktisoncology.com/news-releases/news-release-details/aktis-oncology-announces-pricing-its-upsized-initial-public
Investors in our directory
Funds linked from Aktis Oncology's profile — open a fund page for stage focus and related deal articles.
Related funding articles
Venture Capital Tracker pieces that cover Aktis Oncology's financing or category context.
Last updated: 2026-07-24